Differential (Click to cross reference) aducanumab adverse drug reaction Alzheimer's disease Alzheimer's disease, early onset Alzheimer's disease, treatment of amyloid angiopathy, cerebral amyloid angiopathy, cerebral, Boston criteria amyloid angiopathy, cerebral, inflammatory type amyloid beta protein amyloid beta protein antibodies amyloid-related imaging abnormalities anticoagulant, treatment apolipoprotein E apoliprotein E, plasma level asymptomatic atrial fibrillation atrial fibrillation, treatment biologic markers CAT scan, abnormal CAT scan, emission, abnormal cerebral edema cerebral edema, vasogenic cerebrovascular disease complications confusion contraindications controversies in neurology cost dementia dementia, treatment of diagnostic criteria dizziness gantenerumab headache hemosiderosis of CNS, superficial hemosiderosis, subarachnoid iatrogenic neurologic disorders intellectual deterioration intracerebral hemorrhage intracerebral hemorrhage, lobar intracerebral hemorrhage, small lecanemab left atrial appendage, percutaneous closure mental status, abnormal microhemorrhage, intracerebral mild cognitive impairment mimics monoclonal antibodies MRI, abnormal myoclonus neurologic disease, diagnoses of neuropathology overlap syndrome platelet inhibiting drugs prognosis remternetug review article risk factors safety shared decision making subarachnoid hemorrhage subarachnoid hemorrhage, cerebral convexity symptomatic tissue plasminogen activator, intravenous transient neurologic deficit treatment of neurologic disorder Virchow-Robin spaces, dilated white matter disease white matter disease, subcortical

Showing articles 0 to 7 of 7 Cerebral Amyloid Angiopathy NEJM 394:1836-1845, Greenberg,S.M., 2026 Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease JAMA Neurol 92:19-29, Salloway,S.,et al, 2025 Lecanemab in Early Alzheimers Disease NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023 Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment Neurol 101:1079-1080, Bonami,S.,et al, 2023 Amyloid-Related Imaging Abnormalities:An Update AJR 220:562-575, Roytman,M.,et al, 2023 Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021 10 Things You Should Know About Cerebral Amyloid Angiopathy Stroke 57:e69-e742026, Charidimou,A., Showing articles 0 to 7 of 7